ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Iron chelation therapy and splenomegaly severity in transfusion dependent beta thalassemia major: assessment of ferritin patterns and clinical outcomes.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Splenomegaly is a clinically important complication in transfusion dependent beta thalassemia major because spleen enlargement may worsen anemia, transfusion burden and patient discomfort. This study assessed splenomegaly severity, related clinical burden, serum ferritin patterns and longitudinal clinical outcomes during routine transfusion and chelation care. This cohort study was conducted at Thalassemia Care Centre Nawabshah from March to August 2025. Patients with transfusion dependent beta thalassemia major were enrolled during routine transfusion visits. Baseline and follow up assessments included clinical history, chelation status, hemoglobin, serum ferritin, ultrasound-based spleen length and width and splenomegaly related symptoms. Patients were grouped by splenomegaly severity. Baseline groups were compared and ferritin spleen relationships were examined. Longitudinal changes in hemoglobin, spleen measurements and ferritin were evaluated using repeated measures models. The final cohort comprised 515 patients. Mean age was 7.39 ± 5.47 years, and mean serum ferritin was 2491.91 ± 806.46 ng/mL. Normal spleen was observed in 70 patients (13.6%) while mild, moderate and severe splenomegaly were observed in 190 (37.0%), 196 (38.1%) and 58 (11.3%) patients respectively. Mean spleen length increased from 15.21 ± 3.33 cm in the normal group to 19.33 ± 3.96 cm in the severe group. Moderate pain was reported by 345 patients (67.1%). Ferritin differed across severity groups (p = 0.0016) but showed no direct linear relationship with spleen size. Hemoglobin improved from 7.39 ± 1.74 to 7.62 ± 1.72 g/dL by second follow up. Spleen length decreased from 17.13 ± 3.53 to 15.64 ± 3.46 cm. Baseline hemoglobin was below 9.5 g/dL in 445 of 515 patients (86.4%). The 5-month spleen-length change was modest and does not demonstrate reversal of established hypersplenism. Splenomegaly carried meaningful clinical burden in transfusion dependent beta thalassemia major. Ferritin remained useful for iron overload monitoring, but ultrasound spleen assessment and symptom evaluation added important clinical value during routine transfusion and chelation care. Serum ferritin should not be interpreted as a marker of spleen size.
Indexed as
Identifiers
42696142What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.